Micafungin has a low potential for interactions with medicines metabolised via CYP3A mediated pathways as shown as follows.
Effects of other medicines on micafungin: A total of 14 drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between micafungin and mycophenolate mofetil, cyclosporin, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, rifampicin, itraconazole, voriconazole and amphotericin B. In these studies, no interaction that altered the pharmacokinetics of micafungin was observed. Therefore, no MYCAMINE dose adjustments are necessary when these medicines are administered concomitantly.
Effects of micafungin on other medicines: There was no effect of a single dose or multiple doses of micafungin on mycophenolate mofetil, cyclosporin, tacrolimus, prednisolone, fluconazole and voriconazole pharmacokinetics.
Sirolimus AUC was increased by 21% with no effect on Cmax in the presence of steady-state micafungin compared with sirolimus alone. Nifedipine AUC and Cmax were increased by 18% and 42% respectively, in the presence of steady-state micafungin compared with nifedipine alone. Itraconazole AUC and Cmax were increased by 22% and 11% respectively. Therefore, patients receiving sirolimus, nifedipine or itraconazole in combination with MYCAMINE should be monitored for toxicity and the dosage of sirolimus, nifedipine or itraconazole reduced if necessary.